Ecoza

Tinea Pedis, Inflammation, Fungal eye infections + 17 more

Treatment

20 Active Studies for Ecoza

What is Ecoza

Econazole

The Generic name of this drug

Treatment Summary

Griseofulvin is a broad-spectrum antifungal medication used to treat fungal skin infections. It can be taken orally or given by injection, and is also available as a topical cream. Griseofulvin is also effective against some types of bacteria.

Spectazole

is the brand name

Ecoza Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Spectazole

Econazole

1982

30

Effectiveness

How Ecoza Affects Patients

Econazole is a medication used to treat fungal infections. It works by keeping fungi from getting the nutrients they need to survive and grow. It will not work for infections caused by bacteria or viruses.

How Ecoza works in the body

Econazole stops fungi from forming a healthy cell membrane. It does this by preventing the production of a certain compound, called ergosterol, from occurring. Without ergosterol, the cell membrane becomes permeable, meaning that its contents leak out. Econazole may also work in other ways, such as inhibiting respiration, blocking certain molecules from entering the cell, and stopping the transformation of yeast into a different form.

When to interrupt dosage

The amount of Ecoza is subordinate to the diagnosed condition, including Cellulitis, Tinea cruris and Fungal eye infections. The measure of dosage is contingent upon the method of delivery (e.g. Cream - Topical or Topical) featured in the underneath table.

Condition

Dosage

Administration

Ringworm

, 0.01 mg/mg, 10.0 mg, 150.0 mg, 1.0 %, 10.0 mg/mL

, Topical, Cream, Cream - Topical, Suppository, Suppository - Vaginal, Vaginal, Aerosol, foam, Solution - Topical, Solution, Kit - Topical, Kit, Aerosol, foam - Topical, Cream - Vaginal

Fungal eye infections

, 0.01 mg/mg, 10.0 mg, 150.0 mg, 1.0 %, 10.0 mg/mL

, Topical, Cream, Cream - Topical, Suppository, Suppository - Vaginal, Vaginal, Aerosol, foam, Solution - Topical, Solution, Kit - Topical, Kit, Aerosol, foam - Topical, Cream - Vaginal

Atopic Dermatitis

, 0.01 mg/mg, 10.0 mg, 150.0 mg, 1.0 %, 10.0 mg/mL

, Topical, Cream, Cream - Topical, Suppository, Suppository - Vaginal, Vaginal, Aerosol, foam, Solution - Topical, Solution, Kit - Topical, Kit, Aerosol, foam - Topical, Cream - Vaginal

Intertrigo

, 0.01 mg/mg, 10.0 mg, 150.0 mg, 1.0 %, 10.0 mg/mL

, Topical, Cream, Cream - Topical, Suppository, Suppository - Vaginal, Vaginal, Aerosol, foam, Solution - Topical, Solution, Kit - Topical, Kit, Aerosol, foam - Topical, Cream - Vaginal

Skin

, 0.01 mg/mg, 10.0 mg, 150.0 mg, 1.0 %, 10.0 mg/mL

, Topical, Cream, Cream - Topical, Suppository, Suppository - Vaginal, Vaginal, Aerosol, foam, Solution - Topical, Solution, Kit - Topical, Kit, Aerosol, foam - Topical, Cream - Vaginal

Balanitis candida

, 0.01 mg/mg, 10.0 mg, 150.0 mg, 1.0 %, 10.0 mg/mL

, Topical, Cream, Cream - Topical, Suppository, Suppository - Vaginal, Vaginal, Aerosol, foam, Solution - Topical, Solution, Kit - Topical, Kit, Aerosol, foam - Topical, Cream - Vaginal

cutaneous candidiasis

, 0.01 mg/mg, 10.0 mg, 150.0 mg, 1.0 %, 10.0 mg/mL

, Topical, Cream, Cream - Topical, Suppository, Suppository - Vaginal, Vaginal, Aerosol, foam, Solution - Topical, Solution, Kit - Topical, Kit, Aerosol, foam - Topical, Cream - Vaginal

Tinea Pedis

, 0.01 mg/mg, 10.0 mg, 150.0 mg, 1.0 %, 10.0 mg/mL

, Topical, Cream, Cream - Topical, Suppository, Suppository - Vaginal, Vaginal, Aerosol, foam, Solution - Topical, Solution, Kit - Topical, Kit, Aerosol, foam - Topical, Cream - Vaginal

Tinea Pedis

, 0.01 mg/mg, 10.0 mg, 150.0 mg, 1.0 %, 10.0 mg/mL

, Topical, Cream, Cream - Topical, Suppository, Suppository - Vaginal, Vaginal, Aerosol, foam, Solution - Topical, Solution, Kit - Topical, Kit, Aerosol, foam - Topical, Cream - Vaginal

severe local inflammatory reactions

, 0.01 mg/mg, 10.0 mg, 150.0 mg, 1.0 %, 10.0 mg/mL

, Topical, Cream, Cream - Topical, Suppository, Suppository - Vaginal, Vaginal, Aerosol, foam, Solution - Topical, Solution, Kit - Topical, Kit, Aerosol, foam - Topical, Cream - Vaginal

Eczema

, 0.01 mg/mg, 10.0 mg, 150.0 mg, 1.0 %, 10.0 mg/mL

, Topical, Cream, Cream - Topical, Suppository, Suppository - Vaginal, Vaginal, Aerosol, foam, Solution - Topical, Solution, Kit - Topical, Kit, Aerosol, foam - Topical, Cream - Vaginal

Tinea Versicolor

, 0.01 mg/mg, 10.0 mg, 150.0 mg, 1.0 %, 10.0 mg/mL

, Topical, Cream, Cream - Topical, Suppository, Suppository - Vaginal, Vaginal, Aerosol, foam, Solution - Topical, Solution, Kit - Topical, Kit, Aerosol, foam - Topical, Cream - Vaginal

Inflammation

, 0.01 mg/mg, 10.0 mg, 150.0 mg, 1.0 %, 10.0 mg/mL

, Topical, Cream, Cream - Topical, Suppository, Suppository - Vaginal, Vaginal, Aerosol, foam, Solution - Topical, Solution, Kit - Topical, Kit, Aerosol, foam - Topical, Cream - Vaginal

cutaneous dermatophyte infection

, 0.01 mg/mg, 10.0 mg, 150.0 mg, 1.0 %, 10.0 mg/mL

, Topical, Cream, Cream - Topical, Suppository, Suppository - Vaginal, Vaginal, Aerosol, foam, Solution - Topical, Solution, Kit - Topical, Kit, Aerosol, foam - Topical, Cream - Vaginal

Skin candida

, 0.01 mg/mg, 10.0 mg, 150.0 mg, 1.0 %, 10.0 mg/mL

, Topical, Cream, Cream - Topical, Suppository, Suppository - Vaginal, Vaginal, Aerosol, foam, Solution - Topical, Solution, Kit - Topical, Kit, Aerosol, foam - Topical, Cream - Vaginal

Cellulitis

, 0.01 mg/mg, 10.0 mg, 150.0 mg, 1.0 %, 10.0 mg/mL

, Topical, Cream, Cream - Topical, Suppository, Suppository - Vaginal, Vaginal, Aerosol, foam, Solution - Topical, Solution, Kit - Topical, Kit, Aerosol, foam - Topical, Cream - Vaginal

Shingles

, 0.01 mg/mg, 10.0 mg, 150.0 mg, 1.0 %, 10.0 mg/mL

, Topical, Cream, Cream - Topical, Suppository, Suppository - Vaginal, Vaginal, Aerosol, foam, Solution - Topical, Solution, Kit - Topical, Kit, Aerosol, foam - Topical, Cream - Vaginal

Tinea Cruris

, 0.01 mg/mg, 10.0 mg, 150.0 mg, 1.0 %, 10.0 mg/mL

, Topical, Cream, Cream - Topical, Suppository, Suppository - Vaginal, Vaginal, Aerosol, foam, Solution - Topical, Solution, Kit - Topical, Kit, Aerosol, foam - Topical, Cream - Vaginal

Tinea

, 0.01 mg/mg, 10.0 mg, 150.0 mg, 1.0 %, 10.0 mg/mL

, Topical, Cream, Cream - Topical, Suppository, Suppository - Vaginal, Vaginal, Aerosol, foam, Solution - Topical, Solution, Kit - Topical, Kit, Aerosol, foam - Topical, Cream - Vaginal

Mycoses

, 0.01 mg/mg, 10.0 mg, 150.0 mg, 1.0 %, 10.0 mg/mL

, Topical, Cream, Cream - Topical, Suppository, Suppository - Vaginal, Vaginal, Aerosol, foam, Solution - Topical, Solution, Kit - Topical, Kit, Aerosol, foam - Topical, Cream - Vaginal

Warnings

There are 20 known major drug interactions with Ecoza.

Common Ecoza Drug Interactions

Drug Name

Risk Level

Description

Alfuzosin

Major

The metabolism of Alfuzosin can be decreased when combined with Econazole.

Avanafil

Major

The metabolism of Avanafil can be decreased when combined with Econazole.

Bromocriptine

Major

The serum concentration of Bromocriptine can be increased when it is combined with Econazole.

Cabergoline

Major

The serum concentration of Cabergoline can be increased when it is combined with Econazole.

Cariprazine

Major

The metabolism of Cariprazine can be decreased when combined with Econazole.

Ecoza Toxicity & Overdose Risk

No cases of human overdose on econazole have been reported yet. In animal studies, the lowest dose of econazole that was toxic to mice, rats, guinea pigs and dogs was 462, 668, 272 and 160 mg/kg respectively.

Ecoza Novel Uses: Which Conditions Have a Clinical Trial Featuring Ecoza?

303 active studies are currently examining the possible benefits of Ecoza in the management of Atopic Dermatitis, Eczema and Cellulitis.

Condition

Clinical Trials

Trial Phases

Cellulitis

0 Actively Recruiting

Tinea Versicolor

0 Actively Recruiting

Tinea

0 Actively Recruiting

Inflammation

61 Actively Recruiting

Not Applicable, Phase 2, Early Phase 1, Phase 3, Phase 1

Skin candida

0 Actively Recruiting

Fungal eye infections

0 Actively Recruiting

Tinea Pedis

0 Actively Recruiting

Intertrigo

0 Actively Recruiting

Atopic Dermatitis

17 Actively Recruiting

Phase 2, Phase 3, Not Applicable, Phase 4, Phase 1

Eczema

0 Actively Recruiting

Ringworm

0 Actively Recruiting

Balanitis candida

0 Actively Recruiting

Tinea Pedis

0 Actively Recruiting

cutaneous candidiasis

0 Actively Recruiting

Skin

0 Actively Recruiting

Mycoses

0 Actively Recruiting

Tinea Cruris

0 Actively Recruiting

severe local inflammatory reactions

0 Actively Recruiting

Shingles

2 Actively Recruiting

Phase 2, Phase 1

cutaneous dermatophyte infection

0 Actively Recruiting

Patient Q&A Section about ecoza

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is econazole used for jock itch?

"Econazole is used to treat skin infections such as athlete's foot, jock itch, and ringworm. This medication can also be used for other purposes as prescribed by a doctor."

Answered by AI

Can I use econazole on my face?

"This medicine is for use on the skin only. Do not use it on your eyes, nose, mouth, or vagina. Wash your hands before and after using this medicine."

Answered by AI

What is Ecoza used for?

"Ecoza is a medicine that is used to treat the symptoms of skin fungal infections, candidiasis, and athlete's foot."

Answered by AI

How long does it take for econazole to work?

"In most cases, people notice an improvement in their symptoms after using econazole cream for a week or two. However, it is important to use the cream for the recommended amount of time, even if symptoms have improved, in order to prevent the condition from returning. For most conditions, econazole cream should be used for 2 weeks, while for athlete's foot, it should be used for 1 month."

Answered by AI

Clinical Trials for Ecoza

Image of Texas Tech University Health Sciences Center/ University Medical Center Lubbock in Lubbock, United States.

PSP Monitoring for Sepsis in Burns

18 - 89
All Sexes
Lubbock, TX

The goal of this clinical trial is to learn if using pancreatic stone protein (PSP) test results helps doctors find and treat sepsis earlier in adults with serious burn injuries. The study will also look at whether using PSP is safe and practical in the burn intensive care unit. The main questions it aims to answer are: * Does seeing PSP test results help doctors start the right antibiotics sooner? * Does using PSP reduce unnecessary antibiotic use? * Does using PSP improve recovery and other health outcomes? Researchers will compare two groups of patients. One group will receive standard care, and their PSP test results will be hidden from their care team. The other group will receive standard care, but their care team will be able to see the PSP test results and use them to help make treatment decisions. Participants will: * Be randomly assigned to one of the two study groups. * Have a small blood sample taken within 24 hours after being admitted to the burn ICU and then once each weekday while they are in the ICU. * Receive the usual care for burn injuries and sepsis throughout the study.

Waitlist Available
Has No Placebo

Texas Tech University Health Sciences Center/ University Medical Center Lubbock

Brian Schneider, MD

Abionic SA

Image of Nicholas Institute of Sports Medicine & Athletic Trauma (NISMAT) in New York, United States.

Fruit Juice for Inflammation

18 - 65
All Sexes
New York, NY

Dietary patterns and physical inactivity common in Western societies have been associated with chronic low-grade inflammation and an increased risk of non-communicable health conditions. Fruits and vegetables contain polyphenols and other bioactive compounds that may have antioxidant and anti-inflammatory properties and may influence inflammatory biomarkers. This study will evaluate the effects of increased consumption of a fruit juice on inflammatory biomarkers and exercise capacity in adults with mildly elevated inflammation. Approximately 40 participants will be randomly assigned to consume one of two fruit juice interventions daily for approximately 2 weeks. Changes in C-reactive protein (CRP) and exercise capacity, assessed using a 6-minute walk test, will be evaluated before and after the intervention and compared between the two groups.

Recruiting
Has No Placebo

Nicholas Institute of Sports Medicine & Athletic Trauma (NISMAT)

Christopher Tanayan, MD

Have you considered Ecoza clinical trials?

We made a collection of clinical trials featuring Ecoza, we think they might fit your search criteria.
Go to Trials
Image of University of Utah in Salt Lake City, United States.

Metformin for Muscle Weakness

18+
All Sexes
Salt Lake City, UT

The purpose of this research study is to determine if Metformin taken after anterior cruciate ligament reconstruction (ACLR) surgery can decrease muscle fibrosis, cellular senescence and improve leg strength. ACL injury and surgery increase muscle collagen content and inflammation which slows the recovery of muscle and function and ultimately impacts the quality of life. Individuals enrolled in the study will be randomized to receive metformin (or placebo) for 4 months after surgery. The investigators will measure muscle strength and inflammatory markers in muscle biopsy samples after the intervention period. Investigators will also follow up with participants 8 months later to determine the lasting effects of the intervention.

Phase < 1
Waitlist Available

University of Utah

Micah Drummond

Image of Reichwald Health Sciences Centre in Kelowna, Canada.

Broccoli Sprout Extract + Exercise for Inflammation

19 - 35
All Sexes
Kelowna, Canada

The study consist of 3 interventional periods which will be completed by each consenting participant in a randomized, crossover fashion. The interventional periods will be separated by a minimum 1 week washout period. One of the interventions consists of 4 days of daily supplementation with the commercially available broccoli sprout extract capsules (BrocElite). Another intervention will consist of 4 days of daily supervised treadmill running. The exercise protocol consists of 4 minutes of high-intensity running running followed by a 3 minute recovery period, repeated for a total of 4 repetitions. The last intervention combines the above two and consists of 4 days of daily supplementation and daily supervised exercise training. Before and after each intervention, basic anthropometrics (weight, heart rate, and blood pressure) will be recorded, and a venous blood sample will be collected. Blood samples will be analyzed for metabolic and inflammatory markers. Participants will be asked to refrain from structured exercise, alcohol consumption, and broccoli consumption during each of the experimental periods. Before any testing, willing participants will provide informed consent, and fill out a few demographic, and lifestyle questionnaires. The study will be conducted at the University of British Columbia in Kelowna, BC, Canada.

Recruiting
Has No Placebo

Reichwald Health Sciences Centre

Have you considered Ecoza clinical trials?

We made a collection of clinical trials featuring Ecoza, we think they might fit your search criteria.
Go to Trials
Image of University of Oklahoma Health Campus in Oklahoma City, United States.

Disulfiram for Rheumatoid Arthritis

18 - 75
All Sexes
Oklahoma City, OK

Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by persistent joint inflammation and systemic immune activation. Obesity is common among individuals with RA and is associated with increased disease activity, reduced treatment response, and worse functional outcomes. Inflammation in adipose tissue, driven in part by activation of the NLRP3 inflammasome and downstream gasdermin D (GSDMD)-mediated pathways, may contribute to systemic inflammation and RA disease severity. Disulfiram (DSF), an FDA-approved medication for alcohol use disorder, has recently been identified as an inhibitor of GSDMD-mediated inflammatory signaling and pyroptosis. Preclinical studies suggest that DSF reduces inflammasome activation, inflammatory cytokine release, and metabolic dysfunction. This study is a 12-week, randomized, double-blind, placebo-controlled pilot trial designed to evaluate the safety, tolerability, and preliminary efficacy of DSF in overweight and obese adults with active RA despite stable disease-modifying antirheumatic drug (DMARD) therapy. Participants will be randomized to receive either DSF (250 mg daily) or placebo. The primary objective is to assess safety and tolerability. Secondary and exploratory objectives include evaluating the effects of DSF on systemic inflammation, RA disease activity, metabolic parameters, and adipose tissue inflammasome activation. Findings from this study will inform the feasibility and design of larger clinical trials targeting GSDMD-mediated inflammation in RA.

Phase 2
Waitlist Available

University of Oklahoma Health Campus

Beatriz Y Hanaoka, MD, MSc

Have you considered Ecoza clinical trials?

We made a collection of clinical trials featuring Ecoza, we think they might fit your search criteria.
Go to Trials